Results
A total of 3924 patients were included from 32 studies. A combination of
typical clinical features, heterophile antibodies and EBV-specific
antibodies were used to ascertain diagnosis. The following proportion of
patients had abnormal LFTs: AST (57%); ALT (62%); ALP (65%);
Bilirubin (16%); GGT (41%). Reported median (i.q.r.) time to
resolution of LFT was 8 (6–12) weeks. Maximum time to resolution was
>6 months. Clinical hepatomegaly and splenomegaly were
found in 35% and 44% of patients respectively. Enlarged liver and
spleen on ultrasound were seen in 16/29 (55%) and 38/38 (100%) of
patients respectively. There were no reports of decompensated liver
disease.